Life Science Investing Journey Medical Corporation to Announce Third Quarter 2025 Financial Results on November 12, 2025
Life Science Investing Journey Medical Corporation Reports Combined Emrosi Phase 3 Clinical Trial Efficacy Data Analysis Presented at the 2025 Fall Clinical Dermatology Conference
Life Science Investing Journey Medical Corporation to Participate in October 2025 Investor Conferences
Life Science Investing Journey Medical Corporation to Participate in September 2025 Investor Conferences
LaFleur Minerals Announces Brokered Private Placement of Gold-Linked Convertible Notes to Finance Restart of Gold Production at Beacon Gold Mill
Cardiol Therapeutics' Phase II ARCHER Trial Results to be Presented at the European Society of Cardiology Scientific Meeting on Myocardial & Pericardial Diseases
